Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disease

Overview

This experiment proposes a comprehensive investigation of epigenetic dysregulation in neurodegenerative diseases, focusing on DNA methylation patterns, histone modifications, and non-coding RNA expression in patient brain tissue and iPSC-derived neurons. The study will identify novel epigenetic biomarkers and therapeutic targets.

Hypothesis

Epigenetic dysregulation—including aberrant DNA methylation, altered histone marks, and dysregulated microRNAs—plays a causal role in neurodegeneration rather than being merely a consequence. Reversing these changes will mitigate pathological protein aggregation and neuronal loss.

Specific Aims

Study Design

Phase 1: Epigenomic Mapping (Months 1-8)

• Samples: 50 AD brains, 50 PD brains, 50 age-matched controls (from brain banks)
• Assays:
• Reduced Representation Bisulfite Sequencing (RRBS) for DNA methylome
• ChIP-seq for H3K9ac, H3K27ac, H3K4me3, H3K27me3
• RNA-seq for mRNA and miRNA
• Brain regions: prefrontal cortex, hippocampus, substantia nigra, cerebellum
• Analysis: Differential methylation analysis, histone mark enrichment, co-expression networks

Phase 2: iPSC Validation (Months 9-16)

Overview

This experiment proposes a comprehensive investigation of epigenetic dysregulation in neurodegenerative diseases, focusing on DNA methylation patterns, histone modifications, and non-coding RNA expression in patient brain tissue and iPSC-derived neurons. The study will identify novel epigenetic biomarkers and therapeutic targets.

Hypothesis

Epigenetic dysregulation—including aberrant DNA methylation, altered histone marks, and dysregulated microRNAs—plays a causal role in neurodegeneration rather than being merely a consequence. Reversing these changes will mitigate pathological protein aggregation and neuronal loss.

Specific Aims

Study Design

Phase 1: Epigenomic Mapping (Months 1-8)

• Samples: 50 AD brains, 50 PD brains, 50 age-matched controls (from brain banks)
• Assays:
• Reduced Representation Bisulfite Sequencing (RRBS) for DNA methylome
• ChIP-seq for H3K9ac, H3K27ac, H3K4me3, H3K27me3
• RNA-seq for mRNA and miRNA
• Brain regions: prefrontal cortex, hippocampus, substantia nigra, cerebellum
• Analysis: Differential methylation analysis, histone mark enrichment, co-expression networks

Phase 2: iPSC Validation (Months 9-16)

• Cell lines: 3 AD-iPSC lines, 3 PD-iPSC lines, 3 controls
• Differentiation: Dopaminergic neurons (PD), cortical neurons (AD)
• Epigenetic profiling: Match Phase 1 assays in differentiated neurons
• Functional assays: Neuronal survival, neurite outgrowth, protein aggregation markers

Phase 3: CRISPR Epigenetic Editing (Months 17-22)

• Tools: dCas9-DNMT3A for DNA methylation targeting
• Tools: dCas9-LSD1 for H3K4me1 demethylation
• Targets: Top 10 differentially methylated regions from Phase 1
• Readouts: Gene expression changes, protein aggregation, neuronal viability

Phase 4: Drug Screening (Months 23-28)

• Compound library: 200 FDA-approved epigenetic drugs (HDAC inhibitors, DNMT inhibitors, BET inhibitors)
• Screening platform: Automated microscopy in iPSC-derived neurons
• Hits: 10 compounds for further validation in mouse models

Reagents and Costs

| Item | Cost |
|------|------|
| Human brain tissue (50 AD + 50 PD + 50 controls) | $150,000 |
| RRBS library prep (300 samples) | $90,000 |
| ChIP-seq (1200 samples: 300 × 4 marks) | $180,000 |
| RNA-seq (300 samples) | $75,000 |
| iPSC lines (9 lines) | $45,000 |
| Neuron differentiation reagents | $60,000 |
| CRISPR epigenetic editing constructs | $40,000 |
| Drug library screening | $35,000 |
| Bioinformatics analysis | $50,000 |
| Personnel (2 postdocs, 1 bioinformatician, 24 months) | $360,000 |
| Total | $1,085,000 |

Suggested Investigators

Timeline

• Total: 28 months
• Phase 1: Months 1-8 (epigenomic mapping)
• Phase 2: Months 9-16 (iPSC validation)
• Phase 3: Months 17-22 (CRISPR editing)
• Phase 4: Months 23-28 (drug screening)
• Publication: Month 30

Scoring (10 Dimensions)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Scientific Value | 10 | Addresses fundamental mechanism of epigenetic dysregulation in neurodegeneration |
| Feasibility | 7 | Technically complex but builds on established epigenomics methods |
| Novelty | 10 | First comprehensive epigenomic comparison across AD and PD |
| Disease Impact | 10 | Could identify novel therapeutic targets and biomarkers |
| Reach | 8 | Findings applicable to multiple neurodegenerative diseases |
| Cost Efficiency | 7 | High cost but broad impact across many disease areas |
| Time Efficiency | 6 | 28 months is moderate for comprehensive study |
| Evidence Base | 7 | Some preliminary data exists but large gaps remain |
| Addresses Uncertainty | 10 | Directly tests whether epigenetic changes are causal |
| Translation Potential | 10 | Epigenetic drugs are clinically tractable |

Raw Score: 81/100 Weighted Score: 116.5/140

Cross-Links

• [DNA Methylation](/mechanisms/dna-methylation)
• [Histone Modification](/mechanisms/histone-modification)
• [Epigenetic Therapy](/therapeutics/epigenetic-therapy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tauopathy](/mechanisms/tauopathy)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [HDAC Inhibitors](/therapeutics/hdac-inhibitors)

References

Pathway Diagram

The following diagram shows key molecular relationships for Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disease based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving Epigenetic Regulation Dysfunction in Alzheimer's and Parkinson's Disease discovered through SciDEX knowledge graph analysis: